These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis. Suárez-Otero R; Robles-San Román M; Jaimes-Hernández J; Oropeza-De La Madrid E; Medina-Peñaloza RM; Rosas-Ramos R; Castañeda-Hernández G Proc West Pharmacol Soc; 2002; 45():26-8. PubMed ID: 12434517 [No Abstract] [Full Text] [Related]
44. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Epstein RA Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898 [No Abstract] [Full Text] [Related]
45. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?]. Peretz A Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204 [TBL] [Abstract][Full Text] [Related]
46. New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra). Cotter J; Wooltorton E CMAJ; 2005 May; 172(10):1299. PubMed ID: 15833921 [No Abstract] [Full Text] [Related]
47. FDA advisers endorse Celebrex for juvenile rheumatoid arthritis: lack of studies in children raises safety concerns. Young D Am J Health Syst Pharm; 2007 Jan; 64(1):11-2. PubMed ID: 17189564 [No Abstract] [Full Text] [Related]
48. The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) on chronic periodontitis. Yen CA; Damoulis PD; Stark PC; Hibberd PL; Singh M; Papas AS J Periodontol; 2008 Jan; 79(1):104-13. PubMed ID: 18166099 [TBL] [Abstract][Full Text] [Related]
49. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex). Wynn RL Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547 [No Abstract] [Full Text] [Related]
50. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Bensen WG; Fiechtner JJ; McMillen JI; Zhao WW; Yu SS; Woods EM; Hubbard RC; Isakson PC; Verburg KM; Geis GS Mayo Clin Proc; 1999 Nov; 74(11):1095-105. PubMed ID: 10560596 [TBL] [Abstract][Full Text] [Related]
52. Arthritis: what it is, why you get it and how to stop the pain. Adler J Newsweek; 2001 Sep; 138(10):38-46. PubMed ID: 11550612 [No Abstract] [Full Text] [Related]
53. Why don't we initiate more large simple randomized controlled trials? Wright JM CMAJ; 2003 Nov; 169(11):1170-1. PubMed ID: 14638653 [No Abstract] [Full Text] [Related]
54. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE; Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185 [TBL] [Abstract][Full Text] [Related]
55. [Celebrex: confirmed effectiveness and safety (new data)]. Nasonov EL Ter Arkh; 2001; 73(5):57-61. PubMed ID: 11517753 [No Abstract] [Full Text] [Related]
56. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. Reuben SS; Ekman EF J Bone Joint Surg Am; 2005 Mar; 87(3):536-42. PubMed ID: 15741619 [TBL] [Abstract][Full Text] [Related]
57. [Financial interests characterize published reports on coxiber. Whom can we rely on?]. Håkansson J Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746 [No Abstract] [Full Text] [Related]